Epstein-Barr virus-driven gene therapy for EBV-related lymphomas

Nature Medicine
M FrankenD T Scadden

Abstract

Genetic alterations in malignant tissues are potential targets for gene-based cancer therapies. Alternatively, aberrant expression of certain specific genes associated with malignant transformation may be envisioned to enhance the expression of chemosensitizing drugs. Epstein-Barr virus (EBV)-related B-cell lymphomas are fatal complications of immunosuppression due to AIDS, organ transplantation or congenital immune abnormalities. The malignant cells latently infected with EBV typically express the transcription factor EBNA2 as one of nine latent viral genes. We tested whether an EBNA2-responsive EBV promoter may selectively target EBV-related lymphoma cells by virus-regulated expression of a suicide gene. Using the BamC promoter driving a hygromycin-thymidine kinase fusion gene or controls, we demonstrated that sensitivity to ganciclovir was selectively enhanced in cells expressing EBNA2. Further, there was complete macroscopic regression of established B-cell lymphomas in mice with severe combined immunodeficiency disease (SCID mice) treated with a single course of ganciclovir. These data provide in vitro and in vivo support for a model of exploiting the molecular basis of tumor development to enhance the specificity of gene ...Continue Reading

References

Sep 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·B E HuberT A Krenitsky
Jan 1, 1991·Journal of Virology·U Zimber-StroblG W Bornkamm
Nov 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A CalenderG M Lenoir
Oct 10, 1995·Proceedings of the National Academy of Sciences of the United States of America·X HanY W Kan
Mar 1, 1995·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Y HasegawaK Shimokata
Aug 1, 1995·Nature Genetics·R K HurfordR I Tepper
Aug 2, 1994·Proceedings of the National Academy of Sciences of the United States of America·S R GrossmanE Kieff
Sep 1, 1993·Current Opinion in Oncology·D M Knowles
Sep 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A CarboneM Boiocchi
Apr 30, 1996·Proceedings of the National Academy of Sciences of the United States of America·L T Da CostaB Vogelstein

❮ Previous
Next ❯

Citations

Dec 31, 1998·Springer Seminars in Immunopathology·C L Davis
Mar 24, 2000·Trends in Genetics : TIG·D M NettelbeckR Müller
Jan 1, 1997·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·P J FarrellA Stühler
Jul 13, 2001·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·N D ZilzC G McGregor
Oct 30, 1999·Nihon rinsho. Japanese journal of clinical medicine·F Mizuno
Sep 16, 2003·Molecular and Cellular Biology·Gregory Kennedy, Bill Sugden
Nov 25, 2000·Molecular Pathology : MP·L S YoungA G Eliopoulos
Sep 17, 1998·Japanese Journal of Cancer Research : Gann·H KodairaK Ozawa
Sep 1, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Tulin Budak-AlpdoganJoseph R Bertino
Mar 18, 2005·Molecular Therapy : the Journal of the American Society of Gene Therapy·Md NasimuzzamanShosuke Imai
Apr 1, 2004·Expert Opinion on Therapeutic Patents·Astrid MeerbachPeter Wutzler
Jan 1, 2013·Pathogens·Shigeyoshi FujiwaraKen-Ichi Imadome
May 5, 2007·Expert Reviews in Molecular Medicine·Qian Tao, Anthony T C Chan
Jun 24, 2006·The Oncologist·Ann S LaCasce
Dec 1, 1999·Reviews in Medical Virology·I Johannessen, D H Crawford
Mar 16, 2019·Frontiers in Oncology·Kwai Fung HuiAlan Kwok Shing Chiang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.